1. Home
  2. PLGO vs GENB Comparison

PLGO vs GENB Comparison

Compare PLGO & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pelagos Insurance Capital Limited Common Shares

PLGO

Pelagos Insurance Capital Limited Common Shares

N/A

Current Price

$28.85

Market Cap

2.0B

Sector

Finance

ML Signal

N/A

Logo Generate Biomedicines Inc. Common Stock

GENB

Generate Biomedicines Inc. Common Stock

N/A

Current Price

$12.05

Market Cap

1.7B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
PLGO
GENB
Founded
2014
2018
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
PLGO
GENB
Price
$28.85
$12.05
Analyst Decision
Hold
Strong Buy
Analyst Count
9
6
Target Price
$26.50
★ $27.00
AVG Volume (30 Days)
361.7K
★ 875.3K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
★ 3.05%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$5.49
N/A
Revenue Next Year
$5.68
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.85
$11.00
52 Week High
$29.62
$22.67

Technical Indicators

Market Signals
Indicator
PLGO
GENB
Relative Strength Index (RSI) 73.48 41.38
Support Level $23.95 $11.93
Resistance Level N/A $14.29
Average True Range (ATR) 0.74 1.20
MACD 0.20 -0.08
Stochastic Oscillator 79.57 11.29

Price Performance

Historical Comparison
PLGO
GENB

About PLGO Pelagos Insurance Capital Limited Common Shares

Pelagos Insurance Capital Ltd operates in the specialty insurance and reinsurance sector. Its activities include capital allocation, risk selection, and the deployment of capital through underwriting partnerships across insurance and reinsurance markets. The company manages a diversified portfolio and works with underwriting partners to provide insurance and reinsurance solutions to clients and brokers.

About GENB Generate Biomedicines Inc. Common Stock

Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.

Share on Social Networks: